Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
J Thorac Oncol., Dec;2(12):1112-6 (2007)
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
J Thorac Oncol., Jan;3(1):68-74 (2008)
Late esophageal toxicity after radiation therapy for head and neck cancer.
Head Neck., Feb;32(2):178-83 (2010)
Clinical-dosimetric analysis of measures of dysphagia including gastrostomy-tube dependence among head and neck cancer patients treated definitively by intensity-modulated radiotherapy with concurrent chemotherapy.
Radiat Oncol., 4:52 (2009)
Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
Int. J. Radiat. Oncol. Biol. Phys., Nov;78(4):1026-32 (2010)
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Clin Lung Cancer., Jan;12(1):33-7 (2011)
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
Invest New Drugs., Oct;30(5):2001-7 (2012)
Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer.
Clin Lung Cancer., May;3 Suppl 2:S42-8 (2002)
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Clin Lung Cancer., Jan;5(4):231-6 (2004)
Treatment of extensive small cell lung cancer.
Hematol. Oncol. Clin. North Am., Apr;18(2):373-85 (2004)
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Clin Lung Cancer., Sep;6(2):102-7 (2004)
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
Cancer J., 10(5):294-300 (2004)
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Anticancer Drugs., Mar;16(3):317-21 (2005)
Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries.
Mol. Cancer Ther., May;4(5):806-13 (2005)
Thrombotic thrombocytopenic purpura associated with quetiapine.
Ann Pharmacother., 39(7-8):1346-8 (2005)
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
Clin Lung Cancer., Feb;8 Suppl 2:S61-7 (2007)
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
J Thorac Oncol., Feb;1(2):126-34 (2006)
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Invest New Drugs., Aug;25(4):351-5 (2007)
Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study.
Int. J. Radiat. Oncol. Biol. Phys., Apr;38(1):157-61 (1997)
Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.
Semin. Oncol., Aug;24(4 Suppl 12):S12-110-S12-112 (1997)
Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.
Cancer Biother. Radiopharm., Feb;14(1):31-6 (1999)
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
J. Clin. Oncol., Mar;19(6):1728-33 (2001)
Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
Semin. Oncol., Feb;29(1 Suppl 4):102-9 (2002)
Non-small-cell lung cancer progression after first-line chemotherapy.
Curr Treat Options Oncol., Feb;3(1):53-8 (2002)
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Clin. Cancer Res., Oct;9(12):4356-62 (2003)
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.
Cancer Chemother. Pharmacol., Jul;48(1):22-8 (2001)
Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Cancer Chemother. Pharmacol., 41(1):75-8 (1997)
Severe esophageal toxicity after thoracic radiation therapy for lung cancer associated with the human immunodeficiency virus: a case report and review of the literature.
Am. J. Clin. Oncol., Oct;21(5):479-81 (1998)
Neoadjuvant therapy for non-small cell lung cancer.
Anticancer Drugs., Feb;12 Suppl 1:S5-9 (2001)
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.
Semin. Oncol., Jun;28(3 Suppl 9):26-32 (2001)
Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker.
Br. J. Cancer., Jul;70(1):79-84 (1994)
Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus.
Int. J. Radiat. Oncol. Biol. Phys., Jan;79(1):60-4 (2011)
Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome.
Int. J. Radiat. Oncol. Biol. Phys., Feb;79(2):414-9 (2011)
Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio?
Int. J. Radiat. Oncol. Biol. Phys., Oct;81(2):346-52 (2011)
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Cancer Chemother. Pharmacol., Mar;69(3):835-43 (2012)
Intensity-Modulated Radiotherapy is Associated With Improved Global Quality of Life Among Long-term Survivors of Head-and-Neck Cancer.
Int. J. Radiat. Oncol. Biol. Phys., Sep;84(1):170-5 (2012)
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
J. Clin. Oncol., Nov;24(33):5242-6 (2006)
Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism.
Int. J. Radiat. Oncol. Biol. Phys., 22(4):821-4 (1992)
Gemcitabine in combination with new platinum compounds: an update.
Oncology (Williston Park, N.Y.)., Mar;15(3 Suppl 6):13-7 (2001)
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Cancer., Jul;92(1):146-52 (2001)
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
Cancer Chemother. Pharmacol., 44(6):461-8 (1999)
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Oncology (Williston Park, N.Y.)., Jul;14(7 Suppl 4):26-30 (2000)
The price of remission.
West. J. Med., Mar;166(3):225 (1997)
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer.
J. Clin. Oncol., Sep;16(9):3078-81 (1998)
Co-Author, "LAS0811: From combinatorial chemistry to activation of antioxidant response element."
Journal of Biomedicine & Biotechnology
Co-Author, "Population-based phase I trial of anticancer drugs."
Journal of Oncology
Co-Author, "Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer."
Journal of Clinical Oncology
Co-Author, "A novel small molecule, LAS-0811, inhibits alcohol-induced apoptosis in VL-17A cells."
Biochemical and Biophysical Research Communications
Co-Author, "Maintenance gefitinib orplacebo following concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: A phase III Southwest Oncology Group Study S0023."
Journal of Clinical Oncology